Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)
China
· Delayed Price · Currency is CNY 77.71
-0.56 (-0.72%)
May 14, 2025, 2:45 PM CST
SHE:300573 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2,110 | 1,924 | 1,440 | 1,227 | 1,024 | 683.22 | Upgrade
|
| Other Revenue | 19.49 | 19.49 | 27.86 | 23.2 | 3.6 | 5.46 | Upgrade
|
| Revenue | 2,130 | 1,943 | 1,468 | 1,250 | 1,028 | 688.68 | Upgrade
|
| Revenue Growth (YoY) | 39.11% | 32.42% | 17.42% | 21.59% | 49.26% | 26.96% | Upgrade
|
| Cost of Revenue | 447.31 | 424.53 | 340.36 | 270.08 | 229.01 | 187.87 | Upgrade
|
| Gross Profit | 1,682 | 1,519 | 1,127 | 979.78 | 798.91 | 500.81 | Upgrade
|
| Selling, General & Admin | 892.44 | 875.78 | 689.8 | 595.39 | 456.54 | 321.34 | Upgrade
|
| Research & Development | 229.66 | 220.66 | 167.3 | 145.61 | 88.45 | 63.19 | Upgrade
|
| Other Operating Expenses | 5.77 | 10.68 | 7.16 | 6.66 | 13.8 | 3.14 | Upgrade
|
| Operating Expenses | 1,133 | 1,110 | 867.29 | 748.58 | 558.6 | 388.71 | Upgrade
|
| Operating Income | 549.59 | 408.42 | 259.93 | 231.2 | 240.31 | 112.1 | Upgrade
|
| Interest Expense | -6.61 | -5.71 | -1.44 | -0.94 | -5.99 | -5.94 | Upgrade
|
| Interest & Investment Income | 4.53 | 5.66 | 7.91 | 9.93 | 3.98 | 0.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.11 | 0.2 | -0.09 | -0.13 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.23 | -2.11 | -1.15 | -19.31 | -1.05 | -3.74 | Upgrade
|
| EBT Excluding Unusual Items | 545.17 | 406.15 | 265.45 | 220.79 | 237.12 | 102.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.02 | -0.02 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.95 | -0.98 | -0.04 | 0.42 | 5.16 | -0.08 | Upgrade
|
| Asset Writedown | -22.21 | -14.05 | - | -0 | -0 | - | Upgrade
|
| Other Unusual Items | 8.92 | 3.94 | -0.42 | 12.51 | 1.26 | - | Upgrade
|
| Pretax Income | 530.91 | 395.03 | 264.99 | 233.72 | 243.54 | 102.54 | Upgrade
|
| Income Tax Expense | 81.7 | 56.97 | 24.96 | 22.03 | 34.43 | 9.08 | Upgrade
|
| Earnings From Continuing Operations | 449.21 | 338.06 | 240.04 | 211.68 | 209.11 | 93.46 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -14.41 | -5.48 | Upgrade
|
| Net Income | 449.21 | 338.06 | 240.04 | 211.68 | 194.7 | 87.98 | Upgrade
|
| Net Income to Common | 449.21 | 338.06 | 240.04 | 211.68 | 194.7 | 87.98 | Upgrade
|
| Net Income Growth | 75.86% | 40.84% | 13.39% | 8.72% | 121.31% | 145.11% | Upgrade
|
| Shares Outstanding (Basic) | 175 | 174 | 174 | 172 | 160 | 158 | Upgrade
|
| Shares Outstanding (Diluted) | 176 | 175 | 174 | 172 | 160 | 161 | Upgrade
|
| Shares Change (YoY) | 0.35% | 0.70% | 0.95% | 7.46% | -0.31% | 2.88% | Upgrade
|
| EPS (Basic) | 2.57 | 1.94 | 1.38 | 1.23 | 1.22 | 0.56 | Upgrade
|
| EPS (Diluted) | 2.56 | 1.93 | 1.38 | 1.23 | 1.21 | 0.55 | Upgrade
|
| EPS Growth | 75.24% | 39.86% | 12.32% | 1.18% | 120.42% | 139.95% | Upgrade
|
| Free Cash Flow | 317.45 | 218.27 | 55.61 | -12.96 | 211.9 | 14.01 | Upgrade
|
| Free Cash Flow Per Share | 1.81 | 1.25 | 0.32 | -0.07 | 1.32 | 0.09 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | 2.643 | 0.765 | 0.332 | 0.128 | Upgrade
|
| Dividend Growth | -43.24% | -43.24% | 245.34% | 130.79% | 159.88% | 100.00% | Upgrade
|
| Gross Margin | 79.00% | 78.16% | 76.81% | 78.39% | 77.72% | 72.72% | Upgrade
|
| Operating Margin | 25.81% | 21.02% | 17.71% | 18.50% | 23.38% | 16.28% | Upgrade
|
| Profit Margin | 21.09% | 17.39% | 16.36% | 16.94% | 18.94% | 12.78% | Upgrade
|
| Free Cash Flow Margin | 14.91% | 11.23% | 3.79% | -1.04% | 20.61% | 2.03% | Upgrade
|
| EBITDA | 643.76 | 499.83 | 340.3 | 297.23 | 297.55 | 157.61 | Upgrade
|
| EBITDA Margin | 30.23% | 25.72% | 23.19% | 23.78% | 28.95% | 22.88% | Upgrade
|
| D&A For EBITDA | 94.18 | 91.42 | 80.38 | 66.03 | 57.24 | 45.51 | Upgrade
|
| EBIT | 549.59 | 408.42 | 259.93 | 231.2 | 240.31 | 112.1 | Upgrade
|
| EBIT Margin | 25.81% | 21.02% | 17.71% | 18.50% | 23.38% | 16.28% | Upgrade
|
| Effective Tax Rate | 15.39% | 14.42% | 9.42% | 9.43% | 14.14% | 8.86% | Upgrade
|
| Revenue as Reported | 2,130 | 1,943 | 1,468 | 1,250 | 1,028 | 688.68 | Upgrade
|
| Advertising Expenses | - | 42.52 | 13.81 | 13 | 5.22 | 6.89 | Upgrade
|
Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.